Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on LinkedIn:
“So time for poll – what do you think is the first choice of option in your clinical practice for patients with metastatic HCC, fit, child -Pugh A no comorbidities, no varices, with viral hepatitis, stable liver functions, access to all drugs .
- Atezolizumab plus Bevacizumab
- Nivolumab plus Ipilimumab
- Durvalumab plus Tremelimumab
- Camrelizumab plus Rivoceranib
Vote. Tell me why?”
More posts featuring HCC.